checkAd
    Startseite > Aktien > Galectin Therapeutics > Nachrichten
    Galectin Therapeutics Aktie
    2,8600
     
    EUR
    +1,42 %
    +0,0400 EUR
    Letzter Kurs 13.05.24 Tradegate
    2,7000
     
    EUR
    1.900 STK
    Geldkurs 17:14:07
    2,8400
     
    EUR
    1.800 STK
    Briefkurs 17:14:07
    ISIN: US3632252025 · WKN: A1JV3R · SYM: PHPN · USA

    Neueste Nachrichten

    Galectin Therapeutics to Participate in the H.C. Wainwright BioConnect Conference
    13.05.24 · globenewswire · Galectin Therapeutics
    Galectin Therapeutics Reports the Positive Outcome of the Fifth Data and Safety Monitoring Board Meeting for NAVIGATE Phase 2b/3 Study of Belapectin in Patients with Cirrhotic Portal Hypertension Caused by Metabolic Dysfunction-Associated SteatoHepatitis
    09.04.24 · globenewswire · Galectin Therapeutics
    Galectin Therapeutics Reports 2023 Financial Results and Provides Business Update
    29.03.24 · globenewswire · Galectin Therapeutics
    Galectin Therapeutics Expands Clinical Team with the Appointment of Khurram Jamil, M.D. as Vice President, Clinical Development
    12.03.24 · globenewswire · Galectin Therapeutics
    UPDATE – Galectin Therapeutics Reports Financial Results for the Quarter Ended September 30, 2023 and Provides Business Update
    13.11.23 · globenewswire · Galectin Therapeutics
    Galectin Therapeutics Reports Financial Results for the Quarter Ended September 30, 2023 and Provides Business Update
    13.11.23 · globenewswire · Galectin Therapeutics
    Galectin Therapeutics to Share Five Scientific Presentations at The Liver Meeting 2023, Hosted by the AASLD
    03.11.23 · globenewswire · Galectin Therapeutics
    Galectin Therapeutics to Participate in the H.C. Wainwright 7th Annual NASH Investor Conference on October 24, 2023
    23.10.23 · globenewswire · Galectin Therapeutics
    Galectin Therapeutics Announces Nomination of Dr. Benjamin S. Carson, Sr. to Board of Directors
    12.10.23 · globenewswire · Galectin Therapeutics
    Galectin Therapeutics Reports the Positive Outcome of the Fourth Data and Safety Monitoring Board Meeting for NAVIGATE, its Seamless, Adaptive Phase 2b/3 Study of Belapectin in Patients with Portal Hypertension Caused by Non-Alcoholic SteatoHepatitis Live
    03.10.23 · globenewswire · Galectin Therapeutics
    Galectin Therapeutics to Present Update on its Belapectin Liver Cirrhosis Program at the 20th Edition of Discovery on Target meeting, in Boston, September 25-28, 2023
    26.09.23 · globenewswire · Galectin Therapeutics
    Galectin Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference on September 13, 2023
    13.09.23 · globenewswire · Galectin Therapeutics